News
Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback